These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8789360)

  • 1. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs].
    Artázcoz Sanz MT; Viñes Rueda JJ
    Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease].
    Criado-Alvarez JJ; Romo-Barrientos C; Martínez-Hernández J; González-Solana I
    Rev Neurol; 1998 Sep; 27(157):405-8. PubMed ID: 9774809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
    Martínez-Suárez MM; Blázquez-Menes B
    Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Daily defined doses of parkinsonian drugs in Alcoi].
    Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
    Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The evolution of use of anti-Parkinson drugs in Spain].
    Montané E; Vallano Ferraz A; Castel JM
    Rev Neurol; 2002 Apr 1-15; 34(7):612-7. PubMed ID: 12080509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992-2004).
    Osinaga EA; Inchaurregui LC; Ikobaltzeta IE; Alonso NB; Del Pozo JG
    Parkinsonism Relat Disord; 2007 Dec; 13(8):500-4. PubMed ID: 17532251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence of Parkinson disease in an urban area of the Ciudad de La Habana province, Cuba. Door-to-door population study].
    Giroud Benítez JL; Collado-Mesa F; Esteban EM
    Neurologia; 2000; 15(7):269-73. PubMed ID: 11075574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records.
    van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
    Pharmacoepidemiol Drug Saf; 2001; 10(6):549-54. PubMed ID: 11828838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
    Harris MA; Koehoorn M; Teschke K
    Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incidence of idiopathic and secondary Parkinson disease in Navarre. Population-based case registry].
    Viñes JJ; Larumbe R; Gaminde I; Artázcoz MT
    Neurologia; 1999 Jan; 14(1):16-22. PubMed ID: 10079687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population prevalence and incidence of Parkinson's disease in an Australian community.
    Mehta P; Kifley A; Wang JJ; Rochtchina E; Mitchell P; Sue CM
    Intern Med J; 2007 Dec; 37(12):812-4. PubMed ID: 17561942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease in Spain.
    Grandas F; Kulisevsky J
    Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Punding prevalence in Parkinson's disease.
    Miyasaki JM; Al Hassan K; Lang AE; Voon V
    Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study.
    Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV
    Mov Disord; 2006 Aug; 21(8):1221-5. PubMed ID: 16671076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.